CLPTM1L Promotes Growth and Enhances Aneuploidy in Pancreatic Cancer Cells

• Published in: Cancer research (Chicago, Ill.) Ill.), 2014-05, Vol.74 (10), p.2785-2795
• Main Authors: JINPING JIA, BOSLEY, Allen D, COZEN, Wendy, HERNANDEZ, Brenda Y, LYNCH, Charles F, LONCAREK, Jadranka, ALTEKRUSE, Sean F, LIZHI ZHANG, WESTLAKE, Christopher J, FACTOR, Valentina M, THORGEIRSSON, Snorri, BAMLET, William R, THOMPSON, Abbey, HEWITT, Stephen M, PETERSEN, Gloria M, ANDRESSON, Thorkell, AMUNDADOTTIR, Laufey T, HOSKINS, Jason W, CHEUK, Adam, COLLINS, Irene, PARIKH, Hemang, ZHEN XIAO, YLAYA, Kris, DZYADYK, Marta
• Format: Article
• Language: English
• Subjects: Aneuploidy; Animals; Antineoplastic agents; Biological and medical sciences; Carcinoma, Pancreatic Ductal - genetics; Carcinoma, Pancreatic Ductal - metabolism; Carcinoma, Pancreatic Ductal - pathology; Cell Growth Processes - physiology; Cell Line, Tumor; Chromosome aberrations; Female; Gastroenterology. Liver. Pancreas. Abdomen; HEK293 Cells; Heterografts; Humans; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Medical genetics; Medical sciences; Membrane Proteins - biosynthesis; Membrane Proteins - genetics; Membrane Proteins - metabolism; Mice; Mice, Nude; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Myosin Type II - metabolism; Neoplasm Proteins - biosynthesis; Neoplasm Proteins - genetics; Neoplasm Proteins - metabolism; Pancreatic Neoplasms - genetics; Pancreatic Neoplasms - metabolism; Pancreatic Neoplasms - pathology; Pharmacology. Drug treatments; Subcellular Fractions - metabolism; Tumors
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.can-13-3176

Genome-wide association studies (GWAS) of 10 different cancers have identified pleiotropic cancer predisposition loci across a region of chromosome 5p15.33 that includes the TERT and CLPTM1L genes. Of these, susceptibility alleles for pancreatic cancer have mapped to the CLPTM1L gene, thus prompting an investigation of the function of CLPTM1L in the pancreas. Immunofluorescence analysis indicated that CLPTM1L localized to the endoplasmic reticulum where it is likely embedded in the membrane, in accord with multiple predicted transmembrane domains. Overexpression of CLPTM1L enhanced growth of pancreatic cancer cells in vitro (1.3-1.5-fold; PDAY7 < 0.003) and in vivo (3.46-fold; PDAY68 = 0.039), suggesting a role in tumor growth; this effect was abrogated by deletion of two hydrophilic domains. Affinity purification followed by mass spectrometry identified an interaction between CLPTM1L and non-muscle myosin II (NMM-II), a protein involved in maintaining cell shape, migration, and cytokinesis. The two proteins colocalized in the cytoplasm and, after treatment with a DNA-damaging agent, at the centrosomes. Overexpression of CLPTM1L and depletion of NMM-II induced aneuploidy, indicating that CLPTM1L may interfere with normal NMM-II function in regulating cytokinesis. Immunohistochemical analysis revealed enhanced staining of CLPTM1L in human pancreatic ductal adenocarcinoma (n = 378) as compared with normal pancreatic tissue samples (n = 17; P = 1.7 × 10(-4)). Our results suggest that CLPTM1L functions as a growth-promoting gene in the pancreas and that overexpression may lead to an abrogation of normal cytokinesis, indicating that it should be considered as a plausible candidate gene that could explain the effect of pancreatic cancer susceptibility alleles on chr5p15.33.